Insider Buying: FocalTherics (NASDAQ:FOCL) Director Buys $47,500.00 in Stock

FocalTherics (NASDAQ:FOCL) Director David Horn acquired 10,000 shares of FocalTherics stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average cost of $4.75 per share, with a total value of $47,500.00. Following the completion of the acquisition, the director owned 10,000 shares of the company’s stock, valued at $47,500. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

FocalTherics Stock Performance

FocalTherics stock opened at $4.36 on Thursday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.60 and a quick ratio of 0.99. The firm has a market capitalization of $163.41 million, a price-to-earnings ratio of -4.23 and a beta of -0.04. FocalTherics has a fifty-two week low of $1.30 and a fifty-two week high of $6.40. The firm has a fifty day moving average price of $5.37.

FocalTherics (NASDAQ:FOCL) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). The firm had revenue of $13.20 million during the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 248.00%. As a group, sell-side analysts forecast that FocalTherics will post -0.78 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

FOCL has been the subject of a number of research reports. Piper Sandler restated a “neutral” rating and set a $4.00 target price on shares of FocalTherics in a research report on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of FocalTherics in a research note on Monday. Mizuho set a $15.00 price objective on FocalTherics and gave the stock an “outperform” rating in a research report on Friday, July 17th. Wall Street Zen lowered FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of FocalTherics in a report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $7.75.

Institutional Investors Weigh In On FocalTherics

A number of hedge funds and other institutional investors have recently modified their holdings of FOCL. Leonteq Securities AG purchased a new position in shares of FocalTherics during the fourth quarter valued at approximately $313,000. Kovack Advisors Inc. acquired a new stake in FocalTherics during the fourth quarter worth approximately $53,000. Rock Springs Capital Management LP grew its stake in FocalTherics by 1.3% in the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock worth $4,233,000 after acquiring an additional 16,500 shares during the period. Flax Pond Capital LLC purchased a new stake in FocalTherics in the 4th quarter worth approximately $2,623,000. Finally, SmartHarvest Portfolios LLC acquired a new position in FocalTherics in the 1st quarter valued at $38,000. 62.74% of the stock is currently owned by hedge funds and other institutional investors.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.